2 directors just sold over $5 million of CSL shares each. What's going on?

Why would these two directors sell now when CSL is trading at the lower end of its 52-week price range?

| More on:
A man sits in deep thought with a pen held to his lips as he ponders his computer screen with a laptop open next to him on his desk in a home office environment.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Limited (ASX: CSL) shares have been sluggish of late. Very sluggish.

The stock closed yesterday at $267.95 per share.

Over the past five trading days, CSL has dropped 0.12%. Over the past month, the biotech has fallen 0.21%. The market darling is just "hanging around" at its current price point.

Not inspiring, right?

So, it's interesting to see two directors of the ASX 200 giant selling down personal stakes over the past week. And not just minor stakes, either. We're talking a combined $10 million worth of CSL shares.

And why would they sell now?

CSL shares have traded across a wide price range over the past 12 months — from a 52-week low of $255.87 to a 52-week high of $314.28, so why would they sell at the lower end of this price scale?

Let's investigate.

Two directors hit the sell button on CSL shares

Helpfully, CSL has issued a statement explaining exactly why these two directors have sold some stock.

Company chair Dr Brian McNamee AO, has sold 21,000 shares.

According to the company:

Dr McNamee has sold 21,000 shares. Sale proceeds will be used for philanthropic purposes and to meet personal and taxation obligations.

Dr McNamee will continue to own 125,884 shares in CSL Limited following this transaction, and remains one of CSL's largest private shareholders.

Non-executive director Professor Andrew Cuthbertson has sold 20,000 CSL shares "for philanthropic purposes and as part of a reweighting of his personal investment portfolio".

The company adds:

Professor Cuthbertson will also continue to own a significant interest in the Company's securities, holding 70,391 shares following this transaction.

Should you buy?

As my colleague James reported yesterday, top broker Citi issued a recent note on CSL shares.

It maintained its buy rating but has reduced its official price target from $340 per share to $325 per share.

This implies a potential upside of more than 20% over the next 12 months.

The broker explains:

We adjust our FY24-25e NPATA per share (Core EPS) by 0%/-3%.

Our new TP of $325 (from $340) implies CSL should trade on an FY26 PE of ~26x, in-line with the 10-year average. Maintain Buy.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor Bronwyn Allen has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 small-cap ASX healthcare shares 'with strong prospects'

Fund manager IML discusses why these 3 ASX healthcare shares are likely to rise in value.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

2 All Ords ASX healthcare shares making BIG moves on quarterly updates

These two ASX healthcare companies are seeing heavy trading on Thursday.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

'Trading at a discount': Why now is the time to buy CSL shares

This investing expert says CSL shares now represent an appealing buying opportunity.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

Here's what could impact CSL shares from the biotech's AGM

The biotech giant's leadership had plenty to say.

Read more »

Man with a sleep apnoea mask on whilst sleeping.
Healthcare Shares

Why this fundie is backing ResMed shares in FY25

There's plenty more upside, this fund says.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Healthcare Shares

ResMed shares jump 8% on stellar start to FY25

This high-quality company continues to deliver the goods.

Read more »

Senior woman with caregiver in the garden
Healthcare Shares

A 'golden era' is coming for these ASX healthcare shares

Here's why Blackwattle Partners sees tailwinds ahead for one particular category of healthcare shares.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 200 healthcare stock is rising on big FDA news

Some big news is giving this stock a major lift on Thursday.

Read more »